Control of proliferating potential of myeloid leukemia cells during long-term treatment with vitamin D3 analogues and other differentiation inducers in combination with antileukemic drugs: In vitro and in vivo studies

T. Kasukabe, Y. Honma, M. Hozumi, T. Suda, Y. Nishii

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Growth inhibition of murine and human myeloid leukemia cells by differentiation inducers during long-term culture was examined to improve the strategy for therapy of myeloid leukemia by differentiation inducers. When the effect of 1α,25-dihydroxyvitamin D3, a typical differentiation inducer, on proliferation of mouse myeloid leukemia M1 cells was examined at a constant product of time and concentration (480 nM in 20 days), the continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3 was the most effective for inhibition of cell proliferation. After 20 days, the cumulative cell number was reduced about 3 x 105 times by continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3. Similar results were obtained when M1 cells were treated continuously with dexamethasone. M1 cells resistant to 1α,25-dihydroxyvitamin D3 appeared about 25 days after the start of continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3. On the other hand, when M1 cells were treated continuously with 1α,25-dihydroxyvitamin D3 and noncytotoxic doses of antileukemic drugs such as 1-β-D-arabinofuranosylcytosine and daunomycin, resistant cells did not appear for at least 35 days. A similar effect of 1α,25-dihydroxyvitamin D3 and antileukemic drugs on cell proliferation was observed with the human monoblast-like cell line U937. The survival of syngeneic SL mice inoculated with M1 cells was prolonged more by treatment with both 1α-hydroxyvitamin D3 and daunomycin than by treatment with either drug alone. These results suggest that continuous treatment with both differentiation inducers and certain antileukemic drugs may be more effective therapeutically than treatment with a differentiation inducer alone.

Original languageEnglish
Pages (from-to)567-572
Number of pages6
JournalCancer Research
Volume47
Issue number2
Publication statusPublished - 1987

Fingerprint

Myeloid Leukemia
Calcitriol
Cholecalciferol
Myeloid Cells
Pharmaceutical Preparations
Daunorubicin
Monocyte-Macrophage Precursor Cells
Cell Proliferation
Cytarabine
In Vitro Techniques
Dexamethasone
Cell Differentiation
Cell Count
Cell Line
Survival
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{1b0e2e848f9342e49e1bf0c5ebc9d1ca,
title = "Control of proliferating potential of myeloid leukemia cells during long-term treatment with vitamin D3 analogues and other differentiation inducers in combination with antileukemic drugs: In vitro and in vivo studies",
abstract = "Growth inhibition of murine and human myeloid leukemia cells by differentiation inducers during long-term culture was examined to improve the strategy for therapy of myeloid leukemia by differentiation inducers. When the effect of 1α,25-dihydroxyvitamin D3, a typical differentiation inducer, on proliferation of mouse myeloid leukemia M1 cells was examined at a constant product of time and concentration (480 nM in 20 days), the continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3 was the most effective for inhibition of cell proliferation. After 20 days, the cumulative cell number was reduced about 3 x 105 times by continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3. Similar results were obtained when M1 cells were treated continuously with dexamethasone. M1 cells resistant to 1α,25-dihydroxyvitamin D3 appeared about 25 days after the start of continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3. On the other hand, when M1 cells were treated continuously with 1α,25-dihydroxyvitamin D3 and noncytotoxic doses of antileukemic drugs such as 1-β-D-arabinofuranosylcytosine and daunomycin, resistant cells did not appear for at least 35 days. A similar effect of 1α,25-dihydroxyvitamin D3 and antileukemic drugs on cell proliferation was observed with the human monoblast-like cell line U937. The survival of syngeneic SL mice inoculated with M1 cells was prolonged more by treatment with both 1α-hydroxyvitamin D3 and daunomycin than by treatment with either drug alone. These results suggest that continuous treatment with both differentiation inducers and certain antileukemic drugs may be more effective therapeutically than treatment with a differentiation inducer alone.",
author = "T. Kasukabe and Y. Honma and M. Hozumi and T. Suda and Y. Nishii",
year = "1987",
language = "English",
volume = "47",
pages = "567--572",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Control of proliferating potential of myeloid leukemia cells during long-term treatment with vitamin D3 analogues and other differentiation inducers in combination with antileukemic drugs

T2 - In vitro and in vivo studies

AU - Kasukabe, T.

AU - Honma, Y.

AU - Hozumi, M.

AU - Suda, T.

AU - Nishii, Y.

PY - 1987

Y1 - 1987

N2 - Growth inhibition of murine and human myeloid leukemia cells by differentiation inducers during long-term culture was examined to improve the strategy for therapy of myeloid leukemia by differentiation inducers. When the effect of 1α,25-dihydroxyvitamin D3, a typical differentiation inducer, on proliferation of mouse myeloid leukemia M1 cells was examined at a constant product of time and concentration (480 nM in 20 days), the continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3 was the most effective for inhibition of cell proliferation. After 20 days, the cumulative cell number was reduced about 3 x 105 times by continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3. Similar results were obtained when M1 cells were treated continuously with dexamethasone. M1 cells resistant to 1α,25-dihydroxyvitamin D3 appeared about 25 days after the start of continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3. On the other hand, when M1 cells were treated continuously with 1α,25-dihydroxyvitamin D3 and noncytotoxic doses of antileukemic drugs such as 1-β-D-arabinofuranosylcytosine and daunomycin, resistant cells did not appear for at least 35 days. A similar effect of 1α,25-dihydroxyvitamin D3 and antileukemic drugs on cell proliferation was observed with the human monoblast-like cell line U937. The survival of syngeneic SL mice inoculated with M1 cells was prolonged more by treatment with both 1α-hydroxyvitamin D3 and daunomycin than by treatment with either drug alone. These results suggest that continuous treatment with both differentiation inducers and certain antileukemic drugs may be more effective therapeutically than treatment with a differentiation inducer alone.

AB - Growth inhibition of murine and human myeloid leukemia cells by differentiation inducers during long-term culture was examined to improve the strategy for therapy of myeloid leukemia by differentiation inducers. When the effect of 1α,25-dihydroxyvitamin D3, a typical differentiation inducer, on proliferation of mouse myeloid leukemia M1 cells was examined at a constant product of time and concentration (480 nM in 20 days), the continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3 was the most effective for inhibition of cell proliferation. After 20 days, the cumulative cell number was reduced about 3 x 105 times by continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3. Similar results were obtained when M1 cells were treated continuously with dexamethasone. M1 cells resistant to 1α,25-dihydroxyvitamin D3 appeared about 25 days after the start of continuous treatment with 24 nM 1α,25-dihydroxyvitamin D3. On the other hand, when M1 cells were treated continuously with 1α,25-dihydroxyvitamin D3 and noncytotoxic doses of antileukemic drugs such as 1-β-D-arabinofuranosylcytosine and daunomycin, resistant cells did not appear for at least 35 days. A similar effect of 1α,25-dihydroxyvitamin D3 and antileukemic drugs on cell proliferation was observed with the human monoblast-like cell line U937. The survival of syngeneic SL mice inoculated with M1 cells was prolonged more by treatment with both 1α-hydroxyvitamin D3 and daunomycin than by treatment with either drug alone. These results suggest that continuous treatment with both differentiation inducers and certain antileukemic drugs may be more effective therapeutically than treatment with a differentiation inducer alone.

UR - http://www.scopus.com/inward/record.url?scp=0023101180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023101180&partnerID=8YFLogxK

M3 - Article

C2 - 3466692

AN - SCOPUS:0023101180

VL - 47

SP - 567

EP - 572

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -